Drugs / Demirex
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT06910514 | Jan 2021 → Dec 2022 | colonic neoplasm | Nakafarma S.L. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Demirex | “Researchers will compare the investigational solution (Demirex) to a standard or placebo solution to see if it improves procedural outcomes and safety profiles.” NCT06910514 ↗ |
| Route | Other | “Administered via submucosal injection prior to polyp resection” NCT06910514 ↗ |